SILVERARC CAPITAL MANAGEMENT, LLC — 13F Holdings & Portfolio
CIK 1816307 · latest 13F-HR filed 2026-05-14
SILVERARC CAPITAL MANAGEMENT, LLC manages $979.8M in 13F-reported U.S. long-equity assets across 73 reported positions as of its 2026-03-31 13F-HR filing. Its largest disclosed positions are NZUS (10.75%), KALV (5.91%), DNTH (5.61%). Quarter over quarter (versus its 2025-12-31 filing) the fund opened 21 new positions, exited 18, added to 24, and trimmed 20.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
$979.8M
Long-equity book
73
Distinct positions
2026-03-31
Filed 2026-05-14
+21 / −18 / ↑24 / ↓20
vs 2025-12-31
| Name | Title / Status | Ownership | Type |
|---|
Top Adds (vs prior quarter)
- ERASCA INC$25.1M +511.3%
- DIANTHUS THERAPEUTICS INC$24.0M +77.7%
- KALVISTA PHARMACEUTICALS INC$18.7M +47.7%
- ASCENDIS PHARMA A/S$18.0M +171.6%
- MONTE ROSA THERAPEUTICS INC$16.8M +104.1%
Top Trims
- ABIVAX SA-$23.2M -40.8%
- FRACTYL HEALTH INC-$20.9M -96.4%
- UROGEN PHARMA LTD-$13.7M -33.6%
- VERACYTE INC-$9.3M -61.5%
- INSMED INC-$6.5M -52.7%
New Positions
- ZENAS BIOPHARMA INC$22.2M
- SCHOLAR ROCK HLDG CORP$16.7M
- ALKERMES PLC$16.3M
- DISC MEDICINE INC$12.5M
- HELIX ACQUISITION CORP III$12.3M
Exited Positions
- VIRIDIAN THERAPEUTICS INC$10.8M
- PFIZER INC$10.4M
- AVALO THERAPEUTICS INC$9.5M
- GOSSAMER BIO INC$6.6M
- LEXEO THERAPEUTICS INC$6.1M
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | SPDR SERIES TRUST Put | NZUS | 78464A950 | $105.4M | 10.75% | 825,000 | SH |
| 2 | KALVISTA PHARMACEUTICALS INC | KALV | 483497103 | $57.9M | 5.91% | 2,876,407 | SH |
| 3 | DIANTHUS THERAPEUTICS INC | DNTH | 252828108 | $54.9M | 5.61% | 654,746 | SH |
| 4 | COGENT BIOSCIENCES INC | COGT | 19240Q201 | $50.6M | 5.16% | 1,314,189 | SH |
| 5 | CELCUITY INC | CELC | 15102K100 | $40.9M | 4.17% | 357,903 | SH |
| 6 | IMMUNOME INC | IMNM | 45257U108 | $40.5M | 4.13% | 1,850,278 | SH |
| 7 | KODIAK SCIENCES INC | KOD | 50015M109 | $37.8M | 3.86% | 991,930 | SH |
| 8 | NUVALENT INC | NUVL | 670703107 | $36.4M | 3.71% | 354,914 | SH |
| 9 | ABIVAX SA | ABVX | 00370M103 | $33.7M | 3.44% | 302,530 | SH |
| 10 | MONTE ROSA THERAPEUTICS INC | GLUE | 61225M102 | $32.9M | 3.36% | 2,002,040 | SH |
| 11 | ERASCA INC | ERAS | 29479A108 | $30.0M | 3.06% | 1,851,812 | SH |
| 12 | ASCENDIS PHARMA A/S | ASND | 04351P101 | $28.5M | 2.91% | 124,658 | SH |
| 13 | UROGEN PHARMA LTD | URGN | M96088105 | $27.0M | 2.76% | 1,503,045 | SH |
| 14 | RHYTHM PHARMACEUTICALS INC | RYTM | 76243J105 | $26.6M | 2.72% | 306,000 | SH |
| 15 | PRAXIS PRECISION MEDICINES I | PRAX | 74006W207 | $23.1M | 2.35% | 71,552 | SH |
| 16 | ZENAS BIOPHARMA INC | ZBIO | 98937L105 | $22.2M | 2.27% | 1,135,935 | SH |
| 17 | SYNDAX PHARMACEUTICALS INC | SNDX | 87164F105 | $20.8M | 2.12% | 888,987 | SH |
| 18 | CENTESSA PHARMACEUTICALS PLC | CNTA | 152309100 | $18.5M | 1.89% | 466,345 | SH |
| 19 | SCHOLAR ROCK HLDG CORP | SRRK | 80706P103 | $16.7M | 1.70% | 339,613 | SH |
| 20 | ALKERMES PLC | ALKS | G01767105 | $16.3M | 1.66% | 460,314 | SH |
| 21 | ORIC PHARMACEUTICALS INC | ORIC | 68622P109 | $13.9M | 1.42% | 1,100,010 | SH |
| 22 | DISC MEDICINE INC | IRON | 254604101 | $12.5M | 1.28% | 196,028 | SH |
| 23 | HELIX ACQUISITION CORP III | HLXC | G4444S107 | $12.3M | 1.25% | 1,208,986 | SH |
| 24 | XENON PHARMACEUTICALS INC | XENE | 98420N105 | $11.5M | 1.17% | 197,759 | SH |
| 25 | CG ONCOLOGY INC | CGON | 156944100 | $11.3M | 1.15% | 166,349 | SH |
| 26 | IMMUNOVANT INC | IMVT | 45258J102 | $10.3M | 1.05% | 414,236 | SH |
| 27 | SPYRE THERAPEUTICS INC | SYRE | 00773J202 | $9.4M | 0.96% | 186,618 | SH |
| 28 | BIOGEN INC | BIIB | 09062X103 | $9.3M | 0.95% | 50,967 | SH |
| 29 | GUARDANT HEALTH INC | GH | 40131M109 | $9.1M | 0.93% | 98,514 | SH |
| 30 | VAXCYTE INC | PCVX | 92243G108 | $8.4M | 0.86% | 144,981 | SH |
| 31 | UNIQURE NV Call | — | N90064901 | $8.2M | 0.83% | 500,000 | SH |
| 32 | SAVARA INC | SVRA | 805111101 | $7.8M | 0.80% | 1,430,982 | SH |
| 33 | BENITEC BIOPHARMA INC | BNTC | 08205P209 | $7.6M | 0.78% | 717,725 | SH |
| 34 | SYNDAX PHARMACEUTICALS INC Call | SNDX | 87164F905 | $7.5M | 0.76% | 320,000 | SH |
| 35 | ORUKA THERAPEUTICS INC | ORKA | 687604108 | $7.4M | 0.76% | 150,908 | SH |
| 36 | COMPUGEN LTD | CGEN | M25722105 | $7.1M | 0.72% | 3,315,845 | SH |
| 37 | CELCUITY INC Call | CELC | 15102K900 | $6.2M | 0.63% | 54,500 | SH |
| 38 | TREVI THERAPEUTICS INC | TRVI | 89532M101 | $6.1M | 0.62% | 511,127 | SH |
| 39 | INSMED INC | INSM | 457669307 | $5.9M | 0.60% | 35,850 | SH |
| 40 | VERACYTE INC | VCYT | 92337F107 | $5.8M | 0.59% | 179,700 | SH |
| 41 | CERUS CORP | CERS | 157085101 | $5.8M | 0.59% | 3,176,547 | SH |
| 42 | CELLDEX THERAPEUTICS INC NEW | CLDX | 15117B202 | $5.7M | 0.58% | 178,378 | SH |
| 43 | C4 THERAPEUTICS INC | CCCC | 12529R107 | $5.0M | 0.51% | 1,911,785 | SH |
| 44 | CYTOKINETICS INC | CYTK | 23282W605 | $4.7M | 0.48% | 71,203 | SH |
| 45 | CLIMB BIO INC | CLYM | 28658R106 | $4.7M | 0.48% | 684,908 | SH |
| 46 | COMPASS THERAPEUTICS INC | CMPX | 20454B104 | $4.5M | 0.46% | 859,049 | SH |
| 47 | SURROZEN INC | SRZN | 86889P208 | $4.2M | 0.43% | 144,255 | SH |
| 48 | CONTINEUM THERAPEUTICS INC | CTNM | 21217B100 | $3.9M | 0.40% | 301,729 | SH |
| 49 | ZURA BIO LTD | ZURA | G9TY5A101 | $3.3M | 0.34% | 560,651 | SH |
| 50 | FULCRUM THERAPEUTICS INC | FULC | 359616109 | $3.2M | 0.33% | 419,949 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-03-31 | 2026-05-14 | $979.8M | 73 | 0001420506-26-001011 |
| 2025-12-31 | 2026-02-12 | $720.1M | 68 | 0001420506-26-000321 |
| 2025-09-30 | 2025-11-12 | $741.6M | 82 | 0001420506-25-003142 |